HKTDC welcomes the 2026-27 Budget

HONG KONG, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) – The Hong Kong Trade Development Council (HKTDC) welcomes the 2026–27 Budget delivered this morning by the Financial Secretary of the Hong Kong Special Administrative Region (HKSAR), Paul Chan. The Budget reflects the HKSAR Government’s determination and proactive approach to growing the economy, driving development and improving people’s livelihoods. It focuses on strengthening Hong Kong’s status as an international centre for financial, trade, shipping and I&T, while accelerating new industrialisation and digital transformation.The Budget also supports enterprises in integrating into the country’s overall development and seizing opportunities under the 15th Five-Year Plan. This includes continuously improving the business environment, promoting artificial intelligence and green sustainable development, as well as implementing various measures to consolidate Hong Kong’s unique advantages in connecting the Chinese Mainland and the world.Prof Frederick Ma, Chairman of the HKTDC, said: “The HKTDC welcomes the forward-looking measures in the Budget, including the announcement of the city’s first five-year plan and injecting HK$200 million into the BUD Fund. These initiatives demonstrate the HKSAR Government’s commitment to supporting Hong Kong SMEs and facilitating economic transformation and high-quality development. We will actively align with the Government’s policy direction, implement the national 15th Five-Year Plan, and support Hong Kong in consolidating and enhancing its position as an international financial, shipping and trading centre, while establishing the city as an international hub for I&T and high calibre talents.We will also extend our global business network, further deepen our ties with the ASEAN and Middle Eastern markets and explore more emerging markets. These efforts will further enhance Hong Kong’s pivotal role in the Belt and Road Initiative.”Prof Ma added: “As a superconnector and super value-adder, Hong Kong enjoys the unique edge of linking the mainland and global markets. We successfully bring in international capital, technology, talents and advanced management expertise, helping mainland and local enterprises upgrade and innovate, while supporting mainland companies to go global via Hong Kong’s professional services platform.“As a core member of the GoGlobal Task Force, the HKTDC will further leverage its network of 51 offices worldwide to help businesses explore global markets, diversify risks and achieve growth. We will continue to provide value-added services to Hong Kong enterprises, especially SMEs, empowering them to capitalise on e-commerce opportunities, drive their digital transformation and enhance their competitiveness.”Comprehensive Go-Global Support ServicesThe HKTDC will strengthen its diverse business platforms, including international exhibitions, conferences, business matching, market intelligence and e-commerce support, offering one-stop comprehensive go global assistance, covering brand promotion, supply chain management, professional services matching and risk management.The HKTDC will roll out more concrete measures and support programmes to help Hong Kong and mainland enterprises capitalise on national development strategies and global market opportunities and expand their international business in a sustainable manner.Strengthening I&T ecosystem to help enterprises capture opportunitiesThe Budget introduced a range of measures to promote Hong Kong’s development as an international I&T hub. The HKTDC will continue to actively support the HKSAR Government by integrating I&T elements into its exhibitions, conferences and events. These platforms will help promote Hong Kong’s I&T strengths and ecosystem advantages to mainland and overseas markets, foster cross-industry and cross-regional collaboration and incorporate IP elements to enhance overall competitiveness and effectively protect innovation outcomes.As the flagship event of the Business of Innovation and Technology Week (BIT Week) jointly organised by the Innovation, Technology and Industry Bureau of the HKSAR Government and the HKTDC, InnoEX will once again take place in April to showcase cutting-edge technologies and global innovations, as well as accelerate technology commercialisation and achieve sustainable growth.The HKTDC will continue to leverage Hong Kong’s unique advantages as a global business hub, using its flagship events, efficient business matching and professional service connections to support businesses expand internationally.The Budget also notes that the Asian Financial Forum (AFF) will celebrate its 20th anniversary next year. The HKTDC will work closely with the HKSAR Government to further strengthen AFF’s focus on finance empowering business (Finance +), by leveraging on the Global Business Summit, to enable the financial sector to better serve the real economy and industries with a competitive edge.Media enquiriesHKTDC’s Communications & Public Affairs Department:Agnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgSam HoTel: (852) 2584 4569Email: sam.sy.ho@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEC Implements AI Code Review Service “Metabob,” Reducing Technical Verification Time by Up to 66%

- Spun-Off from NEC X, Metabob Fully Operational for NEC's Internal DX -TOKYO, Feb 25, 2026 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) today announced the operation of "Metabob," an AI-powered code review service for software development. The service is provided by Metabob, Inc., a Santa Clara-based AI startup established through NEC X, Inc.'s new business creation initiatives.Metabob is an important advancement for the development of AI agents, software programs that use AI to autonomously achieve specific goals. The development of AI agents requires both speed and high-quality assurance. However, traditional development processes rely heavily on manual code reviews and maintenance tasks.Existing static analysis tools are limited to syntax-level checks, making it time-consuming to detect, pinpoint, and verify fixes for complex defects. This often leads to prolonged development cycles.Metabob differs from conventional static analysis tools by analyzing code dependencies and execution flow as graph structures. This enables the early detection of complex bugs spanning multiple files, including issues that would otherwise only appear as runtime errors when a program is operating.Furthermore, its proprietary AI model, trained on millions of code-fix examples, can automatically detect bugs, explain what is causing them, and suggest how to fix them.NEC's verification tests of Metabob have reduced labor-hours required for software maintenance and defect fixes as follows:66% reduction compared to manual visual review and manual fixes50% reduction compared to reviews and fixes using coding AI toolsThese results were achieved through NEC’s "Client Zero" initiative, where the company acts as the first user of its own advanced technologies and operational expertise, then shares the insights and value created through this approach with customers and society.Going forward, NEC and NEC X will continue verifying Metabob's effectiveness while exploring its adoption and implementation throughout numerous fields."Companies need AI that can make changes to complex systems while maintaining accuracy and reliability. Through the NEC X program, we gained not only technical and financial support but also access to enterprise customers and investors, including NEC. By conducting repeated verification directly in actual development environments and use cases, we have incorporated the quality and requirements truly demanded by enterprises into our product. Through our collaboration with NEC, we have clearly demonstrated that AI can be safely and effectively utilized in large-scale software development."- Massimiliano Genta, Founder and CEO, Metabob"Metabob's technology is already contributing to operations within the NEC Group and generating concrete results as part of NEC X's efforts to create new business value."We expect Metabob's approach, which combines advanced code analysis technology with generative AI, to become a new standard for safely and practically utilizing AI, even within companies possessing large-scale, mission-critical systems. NEC X will continue contributing to operational efficiency and productivity across society by leveraging the technology and insights we have cultivated to support startup growth."- Shintaro Matsumoto, President and CEO, NEC X"While striving to enhance productivity through AI, prolonged development cycles and application quality have been longstanding challenges. Metabob utilizes AI to streamline and enhance complex code reviews, enabling our teams to focus on more creative and essential development tasks."Through this collaboration with NEC X, insights that are gained internally can be deployed across the entire NEC Group, accelerating innovation."Metabob is a powerful driver for advancing NEC's transformation into an AI-native company. We will continue to actively incorporate cutting-edge technologies and return the results achieved to our customers and society's DX."- Tokuaki Seki, Executive Professional, NEC Corporate IT Systems DivisionAbout NEC XThrough its business creation program (Elev X!), NEC X empowers early-stage startups' journeys to success. The company’s unique blend of collaborative support and resources enables tech entrepreneurs to actualize their ideas into impactful realities that revolutionize the world around us.About NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.For more information, please visit https://www.nec.com, and follow us on LinkedIn and YouTube. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

過半數青少年使用AI完成學業——許多家長並不知情

(SeaPRwire) -   在數位時代養育孩子很困難。要跟上用聊天機器人做作業的孩子更是難上加難。 根據一項研究,超過一半的青少年在課業上求助於人工智慧。這項在2025年9月25日至10月9日對1,458名美國青少年及其父母進行的調查發現,57%的青少年使用AI搜尋資訊,而54%的青少年用它來協助課業。 然而,他們的提問不僅僅是要求聊天機器人定義畢達哥拉斯定理或解釋《梅岡城故事》中布·拉德利這個角色的重要性。事實上,有些青少年可能根本不會去讀哈波·李的這部經典著作,因為研究發現,每10名青少年中就有4人使用聊天機器人來總結文章、書籍和影片。 雖然並非所有人都使用AI來做作業——約45%的青少年聲稱在學校課業上不使用這項技術——但每10人中就有1人承認,他們大部分甚至全部的學校作業都使用AI。約四分之一的青少年表示,這項技術對完成課業非常有幫助或極有幫助,另有四分之一的人表示有些幫助。 「在最高端的應用上,他們用[AI]來研究主題,」皮尤研究中心網路與科技研究主任、該研究的共同作者莫妮卡·安德森告訴媒體。「在最低端的應用上,則是關於編輯。」 父母間的認知差距 但有些青少年向父母隱瞞了他們使用AI的情況,或者至少是在父母不知情的情況下使用這項技術。研究發現,青少年使用AI的情況與父母對子女與這項技術關係的認知之間存在「認知差距」。總計有64%的美國青少年報告使用聊天機器人,但只有51%的父母認為他們的青少年在使用這項技術,還有更多父母完全不知道他們的青少年是否使用AI。「相當大比例的父母,接近十分之三,告訴我們他們不確定自己的孩子是否在使用這些工具,」安德森說。 儘管許多父母對這項技術的能力並不熱衷,但安德森表示,這種認知不匹配的情況在社交媒體使用上並不存在,因為父母更清楚他們的孩子在像和TikTok這樣的應用程式上的存在。「這在很大程度上也因為這仍然是一項非常新的技術,對父母和整個家庭來說也是全新的。」 儘管存在這種差距,大多數父母表示他們可以接受青少年使用聊天機器人來輔助課業,64%的父母贊成用於文章和書籍摘要,58%贊成用於作業協助。 「無摩擦」教育的危險 這項研究發布之際,越來越多的警告指出,AI正在加劇全國範圍內的學習危機。布魯金斯學會一份名為「」的報告將生成式AI視為「」,為學生提供「無摩擦」的成果,卻剝奪了許多學習體驗。 「在其發展軌跡的這一點上,在兒童教育中使用生成式AI的風險超過了其好處,」報告寫道。 布魯金斯學會的研究為學生採用AI制定了一個框架,並提出了學校應如何處理AI使用以及如何在教師、學生和家長中推廣AI素養的建議。 根據皮尤的研究,儘管大多數青少年使用AI來輔助課業,但仍有約四分之一的青少年對這項技術對社會的影響感到擔憂。「最常見的回應是圍繞著這種擔憂,即人們會變得過度依賴,並失去他們的創造力和批判性思維能力,」安德森說。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

Hong Kong Tech Delegation Heading for Market Expansion at Mobile World Congress 2026

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – Hong Kong Trade Development Council (HKTDC), in collaboration with Hong Kong Science and Technology Parks Corporation (HKSTP), will lead a delegation of 21 Hong Kong tech companies and institutions to showcase at Mobile World Congress (MWC) 2026—the world’s premier connectivity event, and debut at 4 Years From Now (4YFN) 2026—a global stage for start-ups, taking place concurrently 2-5 March in Barcelona, Spain.  Building on the momentum from MWC 2025 — the Delegation will be featuring solutions beyond the Connectivity category, covering focus areas across Devices and Systems, Digital Transformation and support from Ecosystem Partners. The Pavilion duet ought to give a more comprehensive picture of Hong Kong’s innovation and technology (I&T) capabilities in engaging global telecom leaders, enterprise decision-makers, industry partners, and investors, bridging cutting-edge research and development (R&D) into real-world applications and propelling Hong Kong’s I&T sector onto the international stage.Iris Wong, Director, Merchandise Trade and Innovation / Director, External Relations, HKTDC, said, “The Hong Kong Tech Pavilion is an ideal platform for Hong Kong tech enterprises to present their latest R&D achievements at major international tech gatherings, support their journey to explore overseas markets, while highlighting Hong Kong’s strengths as an international innovation and technology hub.”Derek Chim, Head of Startup Ecosystem and Development, HKSTP said, “MWC is a global bellwether for communications technology and tech companies at any stage, to connect with the industry and investors, to have a solid ground that validate solutions, catalyse pilot projects, accelerate commercialisation, and scale internationally.”A series of dialogues and exchanges, spanning from networking reception and themed talks to pitching sessions, will take place throughout the events at the Pavilion to facilitate partnerships and investment opportunities for innovative solutions that are market-ready with high potential for market expansion, in particular, Asmote and Cresento under “Connectivity” make stellar examples of the notion:5G & 6G for Communication, Sensing, and AI computing – Shannon & Turing, (Asmote), located at MWC, specialises in mmWave technology for Integrated Sensing and Communication (ISAC) technology—drone communications and control—rising to the occasion as the city advances its low-altitude economy initiatives, while winning favors for its efficiency in managing industrial scenarios such as smart ports and dark factories. The company previously secured the world’s first 26GHz mmWave 5G commercial communications project, demonstrating its leadership in industrial-grade applications.Smart Performance Insights for Sport – Cresento, located at 4YFN, focused on developing an AI-powered shin guard to deliver real-time insights—performance analytics, team leaderboards, and more—with a design that incorporates into gears that athletes already wear and creates minimal friction for, in particular, football players to adapt, will be moving from prototypes to pilot collaborations with European football clubs, academies and sport tech platforms and distributors.HKTDC continues to join hands with HKSTP to support Hong Kong tech enterprises to “go global” by jointly organising the Hong Kong Tech Pavilion to build bridges linking tech companies with the world. This expedites the industry’s progress in internationalisation to meet the growing demand for I&T globally. This will attract talents, facilitate forward-looking investments and explore opportunities globally, realising the mission of entrepreneurs to reach out to the world and further consolidate Hong Kong’s position as an international I&T hub.Mobile World Congress Barcelona (MWC) & 4 Years From Now (4YFN)Date: 2-5 March 2026Venue: Fira Gran Via, Av. Joan Carles I, 64, 08908 L'Hospitalet de Llobregat, Barcelona, SpainHong Kong Tech Pavilion:MWC – Booth 6E44 at Hall 64YFN – Booth 8.1B31 at Hall 8.1Please visit https://bit.ly/MWC2026HKTech for more information on Hong Kong Tech Pavilion and the exhibitors.Appendix: Full list of 21 tech entities showcasing at Hong Kong Tech Pavilion during MWC and 4YFN 2026 (in alphabetical order)No.Name of Tech Company / InstitutionCategoryMWC 2026 – Booth 6E44 at Hall 61Entoptica LimitedDevices & Systems2eSIXConnectivity3Faraconix Technologies Co., Ltd.Connectivity4FreightAmigo Services LimitedDigital Transformation5Glassdio Scientific Company LimitedConnectivity6Harvest Elite International LimitedDigital Transformation7HongKong Umedia LimitedDevices & Systems8iASPEC Services LimitedDigital Transformation9InvestHKEcosystem Partners10Robocore Technology LimitedDevices & Systems11Shannon & Turing Technology LimitedConnectivity12The Hong Kong Polytechnic UniversityEcosystem Partners13Xeroptix TechnologyDevices & Systems4YFN 2026 – Booth 8.1B31 at Hall 8.114AIGM LimitedDigital Transformation15BWSea Technology (HK) Co., LimitedDigital Transformation16Cresento LimitedDevices & Systems17GoGoChart Technology LimitedDigital Transformation18HairCoSys LimitedDevices & Systems19KNQ Technology LimitedDigital Transformation20Solos Technology LimitedDevices & Systems21Vista Innotech LimitedDevices & SystemsAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.About Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 16,000 research professionals and around 2,600 technology companies from 24 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.More information about HKSTP is available at www.hkstp.org.Media Contact: Hong Kong Science and Technology Parks CorporationHong Kong Trade Development CouncilAngela LauTel: +852 6535 7611Email: angela.lau@hkstp.orgWinnie KanTel:  +852 2584 4055Email: winnie.wy.kan@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

維昇藥業(2561.HK)維臻高(R)獲批:重長效生長激素王者登場 重構百億市場的商業天花板

香港, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) - 2026年2月2日,維昇藥業於上海舉辦維臻高(R)(注射用隆培生長激素)獲批上市投資者交流會。 該產品已於1月26日獲得國家藥品監督管理局批准上市。公司在會上表示,維臻高(R)被定位為具備里程碑意義的創新產品 - 不僅是首個在歐美獲批用於兒童的長效生長激素,也是目前臨床研究中唯一被證實在療效上優於日製劑的長效生長激素產品。在生長激素賽道中,隨著多款產品陸續納入醫保、價格體系快速下探,市場競爭格局正在發生變化。維昇藥業以臨床價值和技術壁壘為核心,打造差異化的高端產品路徑。本次交流會由公司管理層系統介紹了產品研發邏輯、臨床數據及當前階段商業化策略的核心思路。本次會議邀請了多位合作夥伴與行業嘉賓出席,包括國婦嬰主任醫師餘文教授、安科生物高級副總裁姚建平先生、副總裁鮑學科先生、上藥控股副總經理宋潞潞女士、上海和睦家醫院長寧院區執行院長劉曉龍先生等到場支持。同時,公司長期股東代表——碧沃投資合夥人柳丹先生亦出席交流,體現了核心股東對公司商業化路徑與長期價值的持續認可。中信證券、東吳證券、天風證券和國海證券等多家大型券商及投資機構亦參與本次會議。一、產品內核:技術壁壘構建差異化護城河1.1 "暫時連接"技術的獨特性在生長激素領域,由於技術壁壘高,實現長效化與保持活性分子的天然結構長期被視為"魚與熊掌不可兼得",而維臻高(R)的研發上市成功突破這一行業技術壁壘,是全球首款實現"長效化+天然結構"作用機理的長效生長激素。維昇藥業首席商務官陳軍在會上詳細拆解了TransCon技術平臺的突破:通過惰性載體(PEG)將天然結構的重組人生長激素暫時包裹和保護起來形成前藥,前藥在注射至皮下時沒有活性,進入血液迴圈在,將惰性載體與生長激素暫時連接起來的TransCon連接結構在體溫與生理pH值下發生自動裂解,7天內以特定的速率逐步釋放出與人體自身分泌完全一致的2.2萬道爾頓(22kD)、191個氨基酸的天然結構的生長激素。這一"暫時連接"機制與市面上其他長效生長激素的"永久連接"形成本質區別。陳軍指出,目前已上市的其他長效生長激素均屬於"生長激素類似物"——其活性分子結構已改變,分子量高達6萬-9萬道爾頓,遠遠高於天然生長激素的2.2萬道爾頓。維臻高(R)進入人體內釋放的活性分子與內源性生長激素的分子量、分子結構、組織分佈以及藥理特性相同,也是首款活性分子是"長效生長激素"而非"生長激素類似物"的長效產品。國婦嬰主任醫師餘文教授從臨床角度補充了關鍵細節:分子量過大的藥物難以穿透緻密的骨骺板,無法發揮生長激素的直接作用,也就可能直接影響療效。維臻高(R)以內源性生長激素的"原藥形式"發揮作用,是其頭對頭研究取得優效結果的理論依據和科學基礎。1.2 說明書上的"法律證據"餘文教授在交流中特別強調,在臨床實踐中,尤其是一款新藥,經國家藥監部門審評並寫入藥品說明書的內容,是判斷藥品療效與安全性的核心法定依據,也是臨床用藥的權威規範標準,它構成了療效與安全性判斷的核心標準,是藥品的"身份證"。維臻高(R)本次獲批的產品說明書直接顯示了其療效優於每日製劑:境外臨床研究結果:"主要療效終點是第52周時年化生長速率(AHV)。本品治療52周時的AHV非劣效並優效於健豪寧(R)組。此外,本品治療後的身高SDS較基線的增加幅度高於健豪寧(R)組。從治療第26周至第52周試驗結束時,對於AHV和身高SDS 較基線的變化,本品組都較健豪寧(R)組更顯著。"中國臨床研究結果:"主要療效終點是第52周AHV。本品治療52周的AHV為 10.66cm/年,相比諾澤(R)組的AHV 9.75cm/年,統計分析結果顯示達到非劣效性以及優效性,即證明了本品治療的52周AHV優效於諾澤(R)組,與境外3期研究結果一致。此外,本品組治療時的身高SDS較基線的增加幅度高於諾澤(R)組,也顯示了優效性。從治療第13周至第52周試驗結束時, 對於AHV和身高SDS較基線的變化,本品組都較諾澤(R)組更顯著。"1.3 安全性設計的雙重保障分子安全性:由於維臻高(R)的活性成分與內源性生長激素結構完全一致,避免了未知分子風險;而其他長效生長激素均為"人造分子",長期安全性存疑(輝瑞、諾和諾德曾嘗試PEG永久修飾技術研發長效生長激素,但均因安全性和療效問題終止研發)。局部安全性:注射部位無活性,避免脂肪萎縮等不良反應。陳軍特別解釋:其他部分長效產品將"7天劑量一次打入一個注射部位",注射部位存在高濃度活性成分;維臻高(R)的"包裹"技術使其在皮下無活性,只在該發揮作用時才呈現活性,降低了導致脂肪細胞溶解、皮膚凹陷的可能,這是"另一個安全性優勢"。更值得關注的是其長期安全性數據:維臻高(R)全球關鍵3期研究治療1年的結果顯示,其不良反應發生的種類與頻率均與生長激素日製劑相似;而在治療時間最長達6年的延長期研究中,維臻高(R)也未出現與生長激素日製劑不同的、新的不良反應類型。餘教授談到,生長激素日製劑在生長激素缺乏症患兒中已有超過40年的使用經驗,其安全性特已被臨床醫生熟知並掌握,基於明確的研究數據,維臻高(R)與日製劑一致的安全性表現,顯然也為醫生的應用提供了更充分的保障。1.4 儲存與使用的便利性突破維臻高(R)在不含防腐劑情況下,室溫(≤30℃)可儲存6個月,在2-8℃條件下可存儲5年,是唯一可在室溫下長期存放的生長激素。餘文教授強調:"這是我們當時完全沒有想到的效期,並且清楚的寫在說明書中。"這一特性對需要攜帶藥物出行、參加夏令營的家庭至關重要。1.5 注射體驗的創新設計維臻高(R)配備電子自動注射筆,由Phillips-Medisize公司生產,2022-2023年獲歐洲和美國三項工業設計大獎(PDA 藥物遞送創新獎、PharmaPack 給藥與包裝創新獎、紅點工業設計獎)。其特點包括:- 單按鈕開關,藥物複溶與注射全自動完成- 隱形針頭設計,患兒看不到針,減少心理恐懼- 配合固定劑量雙腔預充筆芯,注射前無需調節劑量,同時避免浪費- 每月4支筆芯+6支針頭的一體化包裝二、市場策略:技術與臨床優勢下的差異化商業路徑2.1 定價邏輯:突出產品差異化,以技術優勢形成產品價值優勢維昇藥業首席商務官陳軍表示:維臻高(R)的年治療費將會於產品上市時最終確定,但一定會顯著高於其他長效生長激素納入醫保後的價格。但這一定價並非簡單的"高端溢價",而是基於三重錨定:- 價值錨定:產品具備"天然結構+優效+室溫保存"三重獨特屬性,維臻高(R)作為長效生長激素迭代產品,產品的獨特優勢賦予了其核心定價權,將填補高端市場的真空。- 國際錨定:該產品在歐美獲批上市,美國年治療費用50-60萬元,維臻高(R)以其"技術優勢+臨床優勢+歐美品質"為背書,將臨床需求和價值錨點與國際接軌。- 長期健康價值錨定:生長激素治療具有明確的時間窗口和長期獲益特徵。其價值並不取決於單一年度的費用比較,而在於對終身身高結局、心理健康與社會功能的長期改善。從全週期視角衡量,該治療所帶來的健康收益與成本投入之間具有清晰、可解釋的價值邏輯。這一策略的風險在於支付能力,但維昇藥業的判斷是:生長激素市場90%以上為自費,80%以上銷售發生在私立醫院。2.2 管道佈局:合縱連橫的"作戰地圖"維昇藥業作為初創企業,選擇了"輕資產、重合作"的擴張路徑:- 推廣端:與安科生物強強聯手,其高級副總裁姚建平表示,公司在生長激素領域深耕27年,以學術觸達95%的生長激素KOL專家。此次與維昇藥業的合作,"27年經驗+劃時代產品"將形成前所未有的商業化佈局。雙方將按地域區隔運營,維昇藥業自營沿海核心市場,安科生物負責其餘廣闊區域,實現市場的全面覆蓋。- 流通端:上藥控股作為進口分銷平臺,依託其成熟的供應鏈體系,提供從通關到終端的全程服務。上藥控股副總經理宋潞潞指出,維臻高(R)是其經銷的大分子生物藥中,唯一不含防腐劑且可常溫保存6個月的產品,"這兩個優勢在對藥品商業化成功,特別是兒童用藥的商業化成功方面,至關重要"。- 診療端:與和睦家、小蘋果、卓正等高端私立醫院建立深度合作,構建"篩查-診療-管理"的全流程閉環。上海和睦家醫院長寧院區執行院長劉曉龍表示,其患者群體對"技術領先、長期安全"的產品需求明確,維臻高(R)的核心優勢與該群體需求高度匹配,具備良好的臨床土壤。- 流量端:患者及家庭在疾病認知與治療決策過程中,主要通過內容社區、AI 搜索工具及合規的互聯網醫療平臺獲取相關科普資訊,逐步形成以專業性、可及性和合規性為核心的患者資訊入口,讓優質醫療資訊精准觸達目標人群。三、團隊建設:用近乎苛刻的標準篩選最強執行者維昇藥業銷售與商業運營副總裁潘海風詳細介紹了團隊建設的"高強度、嚴標準"體系:- 招聘標準:一線商業化團隊中,約20%具備碩士學歷,80%為醫藥相關本科背景;近三分之一來自其他公司的地區經理級別,整體商業化人員結構和行業經驗顯著高於行業平均水準。- 考核機制:全員"日考+周考+月考",內容涵蓋產品知識、競品知識、臨床醫學、疾病知識;每日考試須達90分以上,集訓落地考不合格者原機遣返,以嚴苛的考核標準保障團隊的專業能力,確保用人標準與產品價值相一致。- 提前佈局:公司提前規劃、前置投入,產品上市前6個月商業化團隊已90%到崗,為產品上市後的快速市場推進做好了充分準備,體現出公司對商業化執行的前置投入與系統規劃。四、其他Q&A環節:問題一:在目前的定價水準下,維臻高(R)的利潤率表現如何?未來隨著地產化推進,盈利空間如何展望? 回答: 公司堅持"先上市、先可及"的策略,進口階段的毛利率足夠產品上市早期的推廣。隨著兩年多後實現地產化生產,即便在當前價格水準大幅下降的情況下,毛利率仍有望達到80%以上。從進口到地產化的路徑清晰,隨著市場規模的持續放量,盈利能力將隨規模放量持續改善。問題二:維臻高(R)在公立醫院與民營醫院中的銷售場景如何落地?在部分長效生長激素已進入國談的背景下,公司如何發揮差異化優勢? 回答: 公司將覆蓋三類管道:公立醫院院內、公立醫院處方外配及民營醫院。受國談因素影響,公立院內並非未來主戰場,核心增長將來自處方外配及民營醫療體系。同時,國家層面已明確提出要有序推進醫師多機構執業,鼓勵醫師依法開展多點執業,醫生在公立醫院與民營醫療機構之間的執業流動性持續提升。這一趨勢為創新、差異化產品在院外及民營場景中的推廣和規範使用創造了有利條件。公司將基於這一制度環境,在所有合規場景中積極佈局。問題三:除維臻高(R)外,公司其他管線在未來幾年的上市節奏及協同貢獻如何? 回答: 公司在內分泌領域已佈局多條管線,其中針對甲狀旁腺功能減退的帕羅培特立帕肽已分別於2024年年初和年底在歐盟跟美國獲批;第三個品種那韋培肽這個月底迎來其 PDUFA 日期,後續產品在中國的上市節奏有望加快。多產品協同放量後,公司整體規模有望持續躍升,長期目標是打造內分泌與代謝領域具備國際競爭力的百億級創新藥企。問題四:已使用短效生長激素的患者,是否可以無縫切換至維臻高(R)?是否有相關臨床證據支持? 回答: 國際3期試驗有一個關於日製劑轉換為隆培生長激素的研究。研究顯示,對於平均使用日製劑已有1.14年、平均劑量為0.29 mg/kg/周的患者,轉為隆培生長激素0.24mg/kg/周後,仍然保持了非常良好的追趕生長的趨勢。這一研究結果證明了由日製劑轉為隆培促生長素每週一次治療仍可保持非常良好的生長趨勢和療效。問題五:維臻高(R)在長期使用方面的療效和安全性表現如何? 回答: 在國際3期試驗的延長期實驗中,患者平均治療4.3年、最長達6年,期間患者身高持續改善,部分患者最終身高SDS甚至超過父母平均身高SDS,充分體現了產品在長期治療中的有效性、安全性及穩定性。問題六:公司目前商業化團隊建設情況如何?與安科生物的合作如何推進? 回答: 公司首年商業化團隊已基本到位,團隊人員以業內資深骨幹為主,強調高專業度、強培訓與嚴格考核。區域運營上,維昇負責沿海一線重點城市,安科覆蓋其他區域,雙方執行統一學術與培訓標準,形成"強強聯合"的銷售體系,共同推進產品的市場落地。五、長期展望:從單一產品到平臺價值維昇藥業執行董事兼首席執行官盧安邦在交流結束的致辭中描繪了公司長期發展的藍圖:維臻高(R)的獲批意味著TransCon技術平臺繼FDA和EMA後獲NMPA認可,為後續產品鋪平道路。在研的帕羅培特立帕肽(甲狀旁腺功能減退症)2024年美歐獲批後首年銷售近40億人民幣,那韋培肽(軟骨發育不全)針對中國1萬患兒的治療剛需。"2026-2028是公司"十年磨一劍"的決戰期,"盧安邦表示,"我們要驗證從臨床、註冊、准入到商業化的端到端能力,最終成為內分泌代謝領域的百億級領軍企業。"本文基於2026年2月2日維昇藥業投資者交流會紀要整理,內容僅供資訊參考,不構成投資建議。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

YCP Launches Operational Transformation Division as Renoir Consulting Transitions to YCP Renoir

Integration expands YCP’s global footprint and reinforces its execution-led transformation capabilities   SINGAPORE – February 25, 2026 – (SeaPRwire) – YCP Holdings (Global) Limited (“YCP”) today announced the launch of its dedicated Operational Transformation Division, as Renoir Consulting (“Renoir”) transitions to operate as YCP Renoir.   The new division will be anchored by YCP Renoir, strengthening YCP’s ability to deliver execution-led transformation and measurable performance improvement. It enhances the firm’s expertise in operational excellence, productivity improvement, cost optimization, and large-scale performance acceleration, combining strategic advisory with hands-on implementation across industries.   As part of the broader transition, affiliated businesses under Renoir will also integrate into YCP. Renoir ESG will be incorporated into YCP’s Sustainability Solutions Division, expanding the firm’s sustainability and climate advisory capabilities. The practice supports organizations across their ESG and climate transformation journeys, delivering practical solutions in decarbonization strategy, governance integration, implementation, and measurable impact realization.   Unison Mining Consulting will operate as YCP Unison, delivering specialized solutions in operational and performance improvement within the mining sector.   The transition also strengthens YCP’s presence across key regions. In addition to expanding its reach in the Americas, where Renoir has an established presence in South America, the integration enhances YCP’s capabilities in the Middle East and Europe, where Renoir has built long-standing client relationships and delivery teams.   The integration further supports collaboration across YCP’s divisions, including its Digital Transformation Division. In Southeast Asia, this strengthens YCP’s ability to deliver technology-enabled transformation initiatives that combine digital strategy, data, AI, and operational execution to drive measurable results.   In line with the integration, the new YCP Renoir website will be unveiled at renoir.ycp.com. The site reflects the firm’s heritage and showcases its execution-led implementation expertise and selected client engagements.   With YCP’s vision of becoming a leading professional services firm across Asia and beyond, this integration strengthens the firm’s operational transformation capabilities, enhances its regional depth across key markets, and expands its global network of seasoned professionals.   About YCP   Founded in 2011, YCP is an Asia-focused consulting firm with presence in over 20+ offices across the globe. We provide advisory services that enable both multinational and local companies to succeed in Asia Pacific and beyond. YCP has developed strong expertise in the Chemicals sector, supporting clients across Southeast Asia, India, Greater China, and beyond. Our dedicated practice combines deep industry knowledge, including chemical engineering and regulatory insight, with strategic consulting capabilities. We help clients navigate market entry, optimize operations, pursue M&A, and implement sustainability and digital transformation initiatives. Through our integrated and localized approach, we enable chemical companies to unlock growth, improve efficiency, and build long-term competitiveness in the region. From plant optimization and Chemical 4.0 strategies to ESG and circular economy transitions, YCP delivers practical solutions tailored to the unique needs of the chemicals industry in Asia.   Media Contact   Brand: YCP  Contact: Melissa Pramesti, Public Relations Lead   Email: pr@ycp.com  Website: https://ycp.com

Domoa Private Limited Launches Initiative to Mainstream 3D-Printed Real Estate in Singapore and Southeast Asia

SINGAPORE – February 25, 2026 – (SeaPRwire) – Domoa Private Limited today announced a strategic initiative to accelerate the adoption of 3D concrete printing (3DCP) across Singapore and the broader Southeast Asian real estate market, positioning the company at the forefront of next-generation construction delivery in the region. The technology is no longer experimental. On construction sites from Dubai to Denmark, and from Texas to the Netherlands, 3D concrete printing has demonstrated that it works, scales, and expands what is possible in real estate development. Yet despite Southeast Asia being one of the world’s most dynamic construction markets, adoption has remained limited. Domoa is moving to change that. A Region Built for 3DCP — That Has Yet to Embrace It Southeast Asia presents one of the most compelling untapped opportunities for 3D concrete printing anywhere in the world. The region is building at pace — luxury resorts, residential clusters, villa developments, boutique hospitality projects — across terrains and climates that demand smart, adaptable construction solutions. Labour costs are rising. Sustainability pressures are intensifying. Clients are more sophisticated than ever and increasingly unwilling to accept the delays, waste, and inconsistency that conventional construction routinely delivers. 3DCP directly addresses these pressures. The technology can reduce build timelines by up to 50 percent, significantly lower material waste, and achieve structural precision beyond traditional manual processes. It enables complex geometries — curved walls, sculpted facades, and organic forms — that would be prohibitively expensive to realise through conventional construction methods. At the same time, 3DCP offers the potential for a lower carbon footprint compared to standard concrete construction. While the technology has been proven internationally, implementation expertise in Southeast Asia has remained limited. Moving from proof-of-concept to delivered, high-quality projects requires coordinated design, technical integration, and disciplined execution. Domoa was established to bridge that gap. Domoa’s Mission: Make 3DCP the Standard, Not the Exception Domoa’s core objective is to embed 3D concrete printing into the mainstream of Singapore’s real estate development, project by project. The company assumes full responsibility for design management on low-rise developments across the region, integrating 3DCP as the primary construction methodology and optimising each project around the technology’s unique strengths. Working with 3D printing-affiliated operators whose industrial-scale printers represent the cutting edge of the sector — alongside architects, developers, and local partners in Singapore — Domoa oversees the entire design and implementation lifecycle. Projects are structured from inception to maximise the advantages of 3DCP: optimised structural forms, efficient material deployment, accelerated construction schedules, and enhanced architectural freedom. The company focuses on luxury low-rise developments, including villas, boutique resorts, residential clusters, and select commercial projects, in markets where adoption conditions are favourable and where its involvement can materially accelerate uptake. Design Optimised for the Technology — and for the People Inside It Adopting 3D concrete printing is not simply a matter of replacing one construction technique with another. To fully realise its potential, projects must be designed from the outset with 3DCP in mind. This is where Domoa’s design management expertise becomes central. Each project led by Domoa is conceived to leverage the strengths of large-scale 3D printing: fluid geometries, continuous structural forms, material efficiency, and high-precision execution. Beyond structural performance, the company integrates passive wellness principles into its design framework — including natural ventilation strategies, solar orientation optimisation, thermal mass utilisation, and biophilic design connections. By aligning advanced construction technology with human-centred architectural thinking, Domoa aims to deliver developments that are not only faster and more sustainable to build, but also healthier, more comfortable, and more responsive to their natural surroundings. About Domoa Domoa Development is Singapore’s first company dedicated to integrating large-scale 3D printing into luxury real-estate development. It is a next-generation real estate development company dedicated to creating resorts that inspire well-being and respect the environment. Media contact Brand: Domoa Contact: Media team Email: info@domoadevelopment.com Website: https://www.domoadevelopment.com/

CanSinoBIO’s Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the “NMPA”), pursuant to which, the supplemental application to expand the age range of applicable population of the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the “MCV4”, trade name: Menhycia (R)) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved by NMPA.This approval marks an important step forward, underscoring the public health impact of Menhycia (R) while also strengthening its long-term commercial prospects. Under China’s current national immunization schedule, the final pre-school dose of meningococcal vaccination is administered at six years of age. For a long time, multivalent conjugate vaccine options for children over age three have been relatively limited in the domestic market. The newly approved expansion of the eligible age range helps address this gap, providing broader and more appropriate vaccination options for this population.At the same time, the broader eligible population is expected to further unlock Menhycia (R)’s commercialization prospects, and lay a more solid foundation for the product’s promotion and strategic rollout in international markets.Notably, CanSinoBIO issued its Results Forecast For The Year 2025 recently. Forecasting total revenue of RMB 1.04–1.08 billion, a year-on-year increase of 22.88% to 27.61% and net profit attributable to the shareholders of RMB 24.5–29.0 million—marking a return to profitability. The company noted that Menhycia (R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, continues to drive sustained revenue growth under its innovation-led commercialization strategy. This also signifies that the company is now reaping the commercial benefits of its early investments in vaccine innovation.Leveraging its proprietary platform, first-mover advantages, and accelerating global expansion, the age expansion of Menhycia (R) is expected to further strengthen CanSinoBIO’s competitive position while providing new momentum for sustainable growth. As product coverage broadens and international commercialization advances, the company is well-positioned to enter a new phase of long-term growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Shoucheng Holdings (00697.HK) Sees Long-Term International Capital Rotation as Robotics Portfolio Enters Harvest Phase

HONG KONG, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) – Shoucheng Holdings Ltd. (00697.HK) drew market attention on Tuesday after its share price experienced volatility alongside certain shareholding adjustments, prompting discussion among investors. A review of the company’s recent disclosures, publicly available trading data and evolving market structure suggests the movement largely reflects short-term capital repositioning rather than any change in fundamentals.Market participants indicated that during the recent market pullback, several international long-only investors executed strategic allocations through block trades and negotiated transactions, facilitating an orderly transition in the company’s shareholder base. Observers said the shift — characterized by a rotation from short-term trading positions to longer-duration institutional capital — could help smooth liquidity fluctuations while enhancing the stability and quality of the shareholder structure.From a capital-markets perspective, the entry of long-term funds typically signals recognition of a company’s medium- to long-term growth trajectory and value realization capacity. Such positioning is widely viewed as laying a firmer foundation for future valuation normalization.Historically, shareholder base optimization and rebalancing often coincide with the stage at which a company’s strategic transformation begins to translate into tangible results. The latest restructuring underscores a more proactive stance by international capital in participating in Shoucheng’s growth story, endorsing its strategic shift from a traditional asset-management platform to a builder of hard-technology industrial ecosystems. The resonance between capital flows and industrial logic is expected to reinforce market confidence in the company’s long-term value proposition.Foreign institutional buying during periods of market weakness reflects confidence in what analysts describe as a structural transformation of Shoucheng’s fundamentals. The company has transitioned from a conventional asset-management model into what it terms an “industrial ecosystem builder.” Through a differentiated “capital + scenario + operations” framework, Shoucheng has established a closed-loop ecosystem, particularly in the robotics sector, where its forward-looking investments have positioned it as a bellwether for hard-technology exposure in Hong Kong equities.The year 2026 is widely regarded by the market as a pivotal window for the accelerated commercialization of embodied artificial intelligence and humanoid robotics. Shoucheng’s systematic early-stage positioning across the robotics value chain is now entering a concentrated realization phase, with portfolio returns demonstrating notable strength.Core projects have generated substantial premiums. Early and concentrated investments in leading companies such as Zibianliang Technology and Unitree Robotics have delivered significant mark-to-market gains. As high-profile holdings including Unitree advance toward initial public offerings, Shoucheng’s equity stakes are poised to transition from unrealized book gains to realized returns and dividend contributions, providing tangible earnings accretion at the listed-company level.Further attention has focused on the high-profile appearance of robotics firms including Unitree Robotics, Galaxy General Robotics and Songyan Dynamics at the 2026 Lunar New Year Gala broadcast by China Central Television, the Year of the Horse edition. Their demonstrations showcased breakthroughs in embodied intelligence, complex motion control and human-machine interaction. The visibility not only strengthened public awareness but also signaled that large-scale commercial deployment may be imminent. As an important early-stage investor in these enterprises, Shoucheng stands to benefit indirectly from both heightened sector visibility and an accelerated commercialization cycle, potentially catalyzing valuation re-rating.Analysts said Tuesday’s trading activity is likely to result in a more diversified shareholder mix. The participation of long-duration international capital may enhance the stock’s global liquidity profile and governance transparency expectations, while also broadening the company’s access to cross-border industrial and strategic resources to support future expansion.Market experience suggests that when a company’s fundamentals enter an upward cycle and structural uncertainties gradually dissipate, shareholder optimization can serve as a catalyst for valuation recovery. According to analysts, the latest rotation in holdings represents a strategic rebalancing of the capital structure, easing short-term supply pressure as the company approaches a value-realization phase.Taken together, Shoucheng appears to be navigating a convergence of three inflection points. First is an industrial inflection, as embodied AI and robotics commercialization accelerate. Second is a capital inflection, with investment projects entering a concentrated realization period. Third is a structural inflection, marked by the entry of long-term international capital and the optimization of the shareholder base.Amid the alignment of global capital endorsement and industrial value dividends, the company’s valuation framework is shifting from that of a traditional asset manager toward that of a hard-technology industrial platform. As industrial deployment advances and investment returns crystallize, market recognition of Shoucheng’s role as an infrastructure builder for the intelligent era may deepen, suggesting that the process of long-term value redefinition has entered a substantive phase. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

首程控股(00697.HK)迎來國際長線接盤 機器人產業生態進入價值收割期

香港, 2026年2月25日 - (亞太商訊 via SeaPRwire.com) - 今日,市場關注到首程控股(00697.HK)股價出現一定波動,疊加個別股份變動安排,引發部分投資者討論。綜合公司近期公告、公開行情數據及市場結構變化情況來看,相關波動更多體現為階段性資金博弈。在資本結構持續優化、產業主線邏輯清晰的背景下,公司基本面未發生實質性變化。市場人士透露,在近期市場調整過程中,部分國際長線資金通過協議及大宗方式完成戰略性布局,實現了籌碼結構的有序轉換。相關觀點認為,這種「短期籌碼向長期資本轉移」的過程,有助於平滑階段性流動性波動,同時提升股東結構的穩定性與質量。從資金屬性看,長線資本的進入往往意味著對公司中長期成長路徑與價值兌現能力的認可,為後續估值修復奠定更加堅實的資金基礎。從資本市場運行規律來看,當企業戰略轉型逐步進入成果兌現階段時,股東結構的優化與再平衡往往同步發生。本輪結構調整所釋放的核心信號在於,國際資金正以更為積極的姿態參與公司成長進程,認可其由傳統資產管理平台向「硬科技產業生態構建者」升級的戰略方向。這種資本與產業邏輯的共振,有助於強化市場對公司長期價值的認知與定價信心。外資機構的逆勢買入,其邏輯支撐源於首程控股基本面的深刻蛻變。公司正從傳統的資產管理平台,成功向「產業生態構建者」轉型。通過獨特的「資本 + 場景 + 運營」三維模式,首程控股已構建起閉環生態,特別是在機器人賽道的前瞻性布局,已使其成為港股硬科技投資的標杆。2026年被市場普遍視為具身智能與人形機器人商業化加速落地的重要時間窗口。首程控股前期在機器人賽道的系統性布局,正在進入集中收穫期,機器人賽道整體投資回報表現亮眼:核心項目實現高溢價。依托對自變量科技、宇樹科技等領軍企業的早期重倉,已實現顯著帳面增值。隨著宇樹科技等明星項目正式開啟IPO衝刺,首程控股持有的股權將迎來從「帳面浮盈」向「現金分紅」的實質性跨越,持續增厚上市公司利潤。此外,值得關注的是,在2026年馬年央視春晚舞台上,宇樹科技、銀河通用、松延動力等機器人企業集體亮相,展示了具身智能技術在複雜動作控制與人機交互方面的突破。這不僅強化了公眾認知,也標誌著相關企業已進入規模化應用前夜。作為上述企業的重要早期布局方,首程控股間接受益於產業熱度與商業化進程提速帶來的估值重估。市場分析人士表示,今日的市場交易將促使公司股東結構更趨多元化。國際長線資金的進入,一方面提升了股票的全球流動性基礎與治理透明度預期,另一方面也為未來產業擴張提供更廣泛的資源協同空間。從市場經驗看,當企業基本面處於上行周期且結構性不確定性逐步消除時,股東結構的優化往往成為估值修復的重要觸發因素。分析人士指出,本輪籌碼調整本質上是資本結構的戰略再平衡,為公司進入價值兌現周期掃清短期供給壓力。綜合來看,首程控股當前處於三重拐點疊加階段。首先是產業拐點——具身智能與機器人商業化加速;其次是資本拐點——投資項目進入集中兌現期;再次是結構拐點——國際長線資本入場優化股東結構。在國際資金認可與產業價值紅利共振之下,公司估值邏輯正從「傳統資管估值框架」向「硬科技產業平台估值框架」切換。隨著產業落地與資本回報逐步兌現,市場對於首程控股作為「智能時代產業基礎設施構建者」的認知將進一步強化,其長期價值重塑進程或已進入實質性階段。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Bitwise 收購 Chorus One 大幅強化機構加密貨幣質押

TLDR Bitwise 收購 Chorus One,快速擴展 30 多個 PoS 網路的質押服務。 Chorus One 交易增加 50 名工程師,以強化 Bitwise 的質押營運。 Bitwise Onchain Solutions 規模擴大,目標是追求收益的機構。 Chorus One 帶來 Solana、AVAX、Sui、NEAR、Aptos 等平台的深厚基礎設施。 此次收購提升了研究、治理追蹤和質押可靠性。 (SeaPRwire) -   Bitwise Asset Management 透過收購 Chorus One,強化其加密貨幣質押業務,進一步推進其擴張策略。該公司旨在擴大其在主要權益證明網路的覆蓋範圍,並提升其技術能力。隨著對結構化加密貨幣質押解決方案的需求持續增長,此次收購使 Bitwise 能夠實現更快的增長。 Bitwise 在其 Onchain 部門下擴展質押能力 Bitwise 將 Chorus One 整合到 Bitwise Onchain Solutions 中,以建立一個更大、更先進的加密貨幣質押平台。該部門現在支援超過 30 個網路的廣泛活動,並管理數十億美元的質押資產。此次收購增加了規模,並創建了一個統一的營運結構,提升了對大型客戶的服務交付。 此外,該公司增加了 50 名技術專業人員,以加強其工程和研究團隊。合併後的團隊現在專注於質押環境中的安全執行和穩定性能。Bitwise 旨在利用這一基礎為全球用戶創建可靠的加密貨幣質押系統。 該公司還加強了對關鍵區塊鏈生態系統的研究覆蓋和治理分析。這項新增功能支援準確的報告,並幫助客戶更有效地追蹤協議變更。Bitwise 預計這些改進將提高其加密貨幣質押活動的透明度和信任度。 Chorus One 帶來主要區塊鏈的技術深度 Chorus One 已在 Solana、Avalanche、Sui、NEAR、Aptos、Tezos 和 TON 等平台建立了基礎設施。該公司在網路可靠性方面建立了良好的記錄,並在其支援的鏈上保持了持續的正常運行時間。其工程團隊提供了技術基礎,使其能夠獲得廣泛的市場覆蓋。 該集團現在加入 Bitwise,擁有八年權益證明領域的營運歷史。這一背景與 Bitwise 對整合加密貨幣質押框架的長期願景相符。兩個組織都共享一種專注於開源工具和性能驅動系統的技術文化。 Chorus One 的領導層透過顧問角色過渡,以支持合併過程。這一轉變實現了連續性,同時允許 Bitwise 指導合併後的路線圖。新結構旨在為大型機構創建一個更先進的加密貨幣質押平台。 Bitwise 強化在數位資產市場的地位 Bitwise 在完成此次收購後,現在擁有近 200 名員工。擴大的員工隊伍支持其向垂直整合模式的更廣泛轉變。該公司現在在單一結構內涵蓋 ETF、基礎設施服務和加密貨幣質押。 隨著機構對以收益為重點的加密策略需求增加,該公司也擴大了其產品基礎。在現貨 ETF 批准鼓勵更結構化的資產管理方法後,這一趨勢加速。Bitwise 計劃將這些產品與加密貨幣質押工具結合,以創造更一致的回報。 此次收購標誌著向更深層次鏈上參與的長期舉措。它也強化了 Bitwise 在全球數位資產生態系統中的存在。該公司將加密貨幣質押視為核心增長動力,因為參與範圍擴展到更多網路。  本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu’s IoT Visualization Solution

Kawasaki, Gunma, Japan, Feb 25, 2026 - (JCN Newswire via SeaPRwire.com) - BEISIA CO., LTD. and Fujitsu Limited today announced that both companies have begun introducing and operating Fujitsu's Advanced Operation & Management offering for digitalizing stores and improving labor productivity at Beisia stores. This solution, part of Fujitsu’s Uvance business model, is being used to automate the temperature management of refrigerator and freezer facilities within stores. The companies plan to implement the solution in all 138 Beisia stores across Japan by May 2026.Introduction of the solution commenced in December 2025This initiative will streamline operations for store employees in complying with HACCP requirements(1), enhancing product freshness management and reducing food loss by providing alert notifications when abnormalities exceeding set thresholds are detected.Under its Uvance business model, which addresses societal challenges, Fujitsu will leverage the knowledge and experience gained from implementing Advanced Operation & Management at Beisia to drive the digitalization of stores through data and AI, enhance labor productivity and promote sustainable store operations.OverviewPrior to the full-scale rollout, Beisia conducted a practical verification of the solution at its Beisia Foods Park Takasaki Kuragano store (Takasaki City, Gunma Prefecture). After confirming the effectiveness of temperature data acquisition and management, as well as the efficiency gains for employees, Beisia decided to implement the solution across all its stores, with sequential deployment beginning in December 2025.Fujitsu's Advanced Operation & Management is a solution that visualizes data acquired from various IoT sensors in real-time. A key feature is its rapid deployment and operation through the attachment of IoT sensors to existing equipment, without dependency on specific hardware.At Beisia, IoT sensors attached to refrigeration and freezing equipment throughout the stores will extract and visualize temperature information in real-time. This eliminates the need for manual inspection and recording by store employees, significantly reducing their workload.Moreover, when abnormalities exceeding thresholds or conditions are detected, alerts are promptly sent to the store's operational communication tools. This enables quicker initial responses to anomalies, strengthening product freshness management, and reducing food loss. Additionally, both headquarters and individual stores can access the same real-time information via a dashboard, facilitating centralized management of information from multiple stores and supporting overall store operation optimization.In Japan, the revised Food Sanitation Act(2) mandates the implementation of HACCP, an international standard for food hygiene management, for all food-related businesses. In the supermarket retail industry, thorough temperature management is crucial for product freshness and consumer trust. However, with a severe labor shortage, streamlining inspection and recording tasks has become an urgent issue.Previously, Beisia stores manually recorded temperatures twice a day for an average of 150 refrigeration and freezing units per store, posing a significant workload for employees. Against this backdrop, Beisia decided to introduce a solution to automate temperature management for its in-store refrigeration and freezing equipment.Figure 1: Overview of Fujitsu's IoT Visualization SolutionFigure 2: IoT Sensor installed in a Beisia store freezer(1) HACCP (Hazard Analysis and Critical Control Point):A food hygiene management method that ensures product safety by identifying and managing critical control points throughout the entire food production process, from raw material reception to product shipment, to eliminate or reduce hazards such as food poisoning bacteria contamination and foreign object mixing.(2) Revised Food Sanitation Act:A law designed to ensure food safety in response to changes in the food environment and globalization. Revised in 2018, it mandated HACCP implementation.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

國泰君安國際獲批使用SIMM 衍生品風險管理接軌國際標準

香港, 2026年2月25日 - (亞太商訊 via SeaPRwire.com) - 2月23日,國泰海通集團下屬公司國泰君安國際控股有限公司(「國泰君安國際」或「公司」,股份代號:1788.HK))宣布,已正式獲得香港證券及期貨事務監察委員會(SFC)批准,自2026年2月12日起可在其兩家持牌機構(國泰君安證券(香港)有限公司及國泰君安外匯有限公司)采用國際掉期與衍生工具協會ISDA標準初始保證金模型(Standard Initial Margin Model, "SIMM" )計算場外衍生品交易的初始保證金。ISDA SIMM 是業界通用的標準方法論,專門用于計算非集中清算衍生品的監管初始保證金。該模型通過建立統一的計算標準,使所有市場參與者得以遵循同一框架進行保證金核算,不僅避免了各機構獨立開發模型所産生的額外成本,還有效减少了因算法差异引發的潜在爭議。其配套的治理框架進一步確立了行業共同實踐,確保保證金計提既符合全球監管要求,又充分保障了保證金的充足性。此次獲批標志著國泰君安國際場外衍生品業務的風險管理能力邁上新台階,在鞏固合規與風控標杆的同時,顯著提升中資券商國際化競爭力。通過采用國際市場通行的SIMM模型,公司得以接軌國際大行標準,能够更精准、高效地管理初始保證金,在有效控制交易對手風險的同時,顯著節省交易成本,實現更高資本效率,增强與全球機構對手方的合作信任,從而提升業務的長期競爭力。此次獲批不僅是對公司衍生品業務技術實力的認可,更是監管機構對公司內部控制、尤其是風險管理能力的又一里程碑式肯定。展望未來,國泰君安國際將進一步精進衍生品業務的內控管理體系,築牢長遠穩定發展的根基。同時,作爲香港資本市場的重要一員,公司將一如既往地配合監管機構,深度參與市場基礎設施建設,助力提升香港場外衍生工具市場的國際競爭力與活力。關於國泰君安國際國泰海通集團下屬公司國泰君安國際(股票代號:1788.HK),是中國證券公司國際化的先行者和引領者,公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地,幷在新加坡、越南和澳門設立子公司,業務覆蓋全球主要市場,爲客戶境外資産配置提供高品質、多元化的綜合性金融服務,核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前,國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級,MSCI ESG「A」評級, Wind ESG「A」評級及商道融綠ESG「A」評級,同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券(股票代號:601211.SH/2611.HK)爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

美聯儲推動移除銀行監管政策中的聲譽風險

摘要 美聯儲提議擬定規則,將「聲譽風險」從銀行監管中移除 公眾意見需在《聯邦公報》公告後 60 天內提交 檢查人員被指示需專注於重大財務風險與合規風險 政策指出銀行不應僅因合法活動而拒絕提供服務 (SeaPRwire) -   美聯儲理事會已就一項提案徵求公眾意見,旨在將從銀行監管框架中移除「聲譽風險」的做法編纂成文。此項請求繼 6 月份採取的初步措施之後,當時已從檢查計畫中刪除了該概念。 理事會表示,該提案旨在確保監管決策依賴於重大財務風險。它還旨在提高監管的清晰度和一致性。意見將在《聯邦公報》發布後的 60 天內被接受。 The Fed moves to eliminate “reputation risk” from oversight policy. — Digital Assets Daily (@AssetsDaily) 負責監管的副主席 Michelle W. Bowman 談到了對「斷開銀行服務」(debanking)的擔憂。「我們聽到了令人不安的斷開銀行服務案例——即監管機構利用對聲譽風險的擔憂,向金融機構施壓,要求其因客戶的政治觀點、宗教信仰或參與不受歡迎但合法的業務而斷開與客戶的銀行服務關係,」她表示。 Bowman 補充道,基於此類理由的歧視是非法的,在美聯儲的監管框架中沒有立足之地。理事會指出,僅憑合法活動不足以成為關閉帳戶或拒絕提供服務的理由。 專注於可衡量的財務風險 擬議規則指示檢查人員專注於具體且可量化的風險。這些風險包括信用風險、流動性風險、操作風險和合規失敗。理事會表示,監管行動必須以證據和記錄在案的發現為基礎。 根據該提案,檢查人員不應引用與合法客戶活動相關的聲譽風險。相反,他們必須評估銀行的風險管理是否符合安全和穩健標準。理事會表示,這種方法將促進可預測的監管流程。 監管機構指出,此項變更並不會削弱監管。銀行仍必須維持強有力的內部控制並遵守適用的法律和法規。監管人員將繼續評估治理和風險管理實務。 解決對「斷開銀行服務」的擔憂 美聯儲的舉措是在有報導稱某些行業面臨銀行服務減少的情況下做出的。數位資產和加密貨幣等領域的一些公司將帳戶終止歸因於聲譽風險的擔憂。 理事會指出,金融機構不應僅因企業從事合法但具爭議的行業而終止帳戶。它強調,合法企業必須根據財務風險和合規記錄進行評估。 提案概述指出,監管指導必須避免模糊的標準。檢查人員被指示在引用缺陷時必須提供明確的理由。理事會表示,這將有助於銀行理解預期並做出有效回應。 此項變更也符合理事會聲明的對核心財務風險的關注。通過從監管政策中移除聲譽風險,監管機構試圖將監管集中於可衡量的因素。這包括資本充足率、資產質量、收益和流動性。 公眾意見徵集流程與後續步驟 {p>理事會發布了擬議規則供公眾審查。利益相關者,包括銀行和消費者團體,可在 60 天期限內提交意見。在審查反饋後,理事會可能會修訂並最終確定該規則。 該提案建立在先前公告的基礎上,並反映了理事會當前的監管理念。它指出,公平獲得金融服務必須與安全和穩健標準相一致。監管行動必須保持與法律和證據的聯繫。 如果獲得通過,該規則將正式把聲譽風險從美聯儲監管政策中移除。理事會表示,這將在維持監管合規要求的同時,為監管決策提供更高的精確度。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China

SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication. Impressive phase III trial data in AD Its Priority Review is expected to accelerate its NDA approval Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas. Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated. Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date. Building an integrated AD solution, strengthening Dermavon’s leadership in dermatology AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care. Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3]. The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/